Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 23Gastrointestinal 14Head & Neck 11Gynecologic 3Dermatologic 3Sarcoma 2Lymphoid 2Breast 2CNS 1

Conditions

Melanoma 3

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × endostar protein × Dermatologic × Clear all
NCT06965231 2025-05-11

FUMS-EDJS2024

Fudan University

Phase 2 Recruiting
58 enrolled
Dermatologic

Melanoma

NCT05907512 2023-06-22

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Fudan University

Phase 2 Unknown
43 enrolled
Dermatologic

Melanoma

NCT03095079 2017-03-29

Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡